GLP-1 Peptides in the UK: Research Compounds vs Licensed Medicines

Search for “GLP-1 peptides UK” and you will find a market that mixes licensed medicines with research compounds and unapproved products. The GLP-1 receptor is a validated drug target, and several licensed medicines act on it. But not every compound that activates the GLP-1 receptor is a licensed medicine, and the regulatory status of each compound matters for how it can be legally accessed.

This guide explains what GLP-1 peptides are, how they work, which compounds are licensed in the UK, which are investigational, and how the research-grade supply of these compounds differs from the licensed medicine market.

What GLP-1 peptides are

GLP-1 stands for glucagon-like peptide-1, a naturally occurring hormone produced in the gut in response to food intake. The hormone stimulates insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces appetite. These effects make the GLP-1 receptor an attractive target for the treatment of type 2 diabetes and obesity.

GLP-1 peptides are synthetic compounds that mimic the action of the natural hormone at the GLP-1 receptor. The first generation of these compounds, such as exenatide, were derived from the saliva of the Gila monster. Later compounds, such as liraglutide and semaglutide, were designed to have longer half-lives and better efficacy. A study published in the New England Journal of Medicine (the STEP 1 trial) evaluated once-weekly semaglutide in adults with overweight or obesity.

More recent compounds have expanded the mechanism beyond the GLP-1 receptor. Tirzepatide is a dual agonist that activates both GIP and GLP-1 receptors. Retatrutide is a triple agonist that activates GIP, GLP-1, and glucagon receptors.

Which GLP-1 peptides are licensed in the UK

Several GLP-1 peptides have received marketing authorisations from the MHRA and are available by prescription in the UK.

The licensed compounds have undergone clinical trials and received regulatory review. They are available by prescription for specific indications. Retatrutide has not received a marketing authorisation from the MHRA. The MHRA states that outside authorised clinical trials, any products sold in the UK claiming to contain retatrutide are likely to be illegal.

How GLP-1 peptides work

GLP-1 peptides activate the GLP-1 receptor, which is expressed on pancreatic beta cells, in the gut, and in the brain. Activation of the receptor produces several effects.

Increased insulin secretion. GLP-1 receptor activation stimulates the release of insulin from pancreatic beta cells in a glucose-dependent manner, meaning that insulin is released only when blood glucose is elevated.

Suppressed glucagon secretion. GLP-1 receptor activation suppresses the release of glucagon, a hormone that raises blood glucose.

Slowed gastric emptying. GLP-1 receptor activation slows the rate at which food leaves the stomach, which contributes to a feeling of fullness.

Reduced appetite. GLP-1 receptor activation acts on the hypothalamus to reduce appetite and food intake.

The New England Journal of Medicine study of liraglutide (the SCALE trial) evaluated 3.0 mg liraglutide for weight management in adults with obesity, or overweight with related conditions, who did not have type 2 diabetes.

The difference between licensed medicines and research compounds

Researchers need to understand the distinction between licensed medicines and research compounds. The two categories are regulated differently, documented differently, and accessed differently.

A licensed medicine has received a marketing authorisation from a regulatory agency after a review of its safety, efficacy, and quality data. It is available by prescription for specific indications. The prescribing information provides detailed guidance on dosing, contraindications, and adverse effects.

A research compound is sold for laboratory use only. It is not approved for human use, and it is not dispensed by pharmacies. The research-use-only designation is a legal boundary that restricts the product to laboratory use. The certificate of analysis is the document that establishes identity, purity, and content.

The Alta Peptides guide to GLP-1 receptor agonists explains the differences between the two categories.

The MHRA enforcement context

The MHRA has been active in enforcing against illicit supply of unlicensed weight loss medicines. The agency’s record seizure announcement described the dismantling of an illicit weight loss medicine production facility in Northampton, with more than 2,000 unlicensed retatrutide and tirzepatide pens seized. The agency stated that these products were being produced in unregulated conditions and sold online to UK consumers.

The agency warned that prescription medicines should only be obtained from a registered pharmacy against a prescription, because products sourced any other way come with no guarantee of what they contain and some may be contaminated with toxic substances.

For researchers, the practical implication is that the compliance posture of a supplier matters. A supplier that maintains a research-use-only boundary and publishes analytical documentation is operating within a recognised research supply channel. A supplier that markets GLP-1 peptides for human use is operating outside that boundary.

The researcher’s verification checklist

1. Lot-specific certificate of analysis

A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published. The Alta Peptides retatrutide product page lists the current lot documentation alongside the price.

2. Complete analytical panel

A certificate that lists only “purity: 99%” is incomplete. The useful fields are identity by mass spectrometry, purity by HPLC, measured content, endotoxin, and sterility. If a supplier’s COA omits measured content or endotoxin, that is a gap.

3. Named independent laboratory

The testing laboratory should be identified and should be a different organisation from the supplier. In the UK, UKAS accreditation is the recognised mark of competence for testing laboratories.

4. Research-use-only boundary

The listing should not publish dosing, administration, or human-use content. A supplier that maintains the boundary consistently is easier to trust than one that publishes human-use content alongside the RUO label.

How Alta Peptides approaches GLP-1 documentation

Alta Peptides is a UK-based research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s certificates page collects the reports for all products. The comparison of retatrutide and tirzepatide explains the mechanistic differences between the two compounds.

Comparing GLP-1 compound categories

Common questions about GLP-1 peptides in the UK

Which GLP-1 peptides are licensed in the UK?

Liraglutide, semaglutide, and tirzepatide have received marketing authorisations from the MHRA. They are available by prescription for specific indications. Retatrutide has not been licensed, and the MHRA states that outside authorised clinical trials, products sold in the UK claiming to contain it are likely to be illegal.

What is the difference between a licensed medicine and a research compound?

A licensed medicine has received a marketing authorisation after a review of its safety, efficacy, and quality data. A research compound is sold for laboratory use only and is not approved for human use. The two categories are regulated differently and documented differently.

How do GLP-1 peptides work?

GLP-1 peptides activate the GLP-1 receptor, which is expressed on pancreatic beta cells, in the gut, and in the brain. Activation of the receptor increases insulin secretion, suppresses glucagon secretion, slows gastric emptying, and reduces appetite.

What should a research-grade GLP-1 COA show?

A complete COA should report identity by mass spectrometry, purity by HPLC with the method stated, measured content or assay value, endotoxin testing, and sterility testing. It should also include the lot number, the testing laboratory’s name, the report ID, and the dates of sample receipt and result reporting.

How do I verify that a COA is real?

Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity.

What should I do if a supplier’s listing makes health claims?

Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern that regulators have cited in enforcement actions.